Skip to content

Study on the efficacy of azithromycin combined with nidanib in the treatment of idiopathic pulmonary fibrosis

Study on the efficacy of azithromycin combined with nidanib in the treatment of idiopathic pulmonary fibrosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084928
Enrollment
Unknown
Registered
2024-05-28
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

control group:nidanib
experimental group:azithromycin combined with nidanib

Sponsors

Tongren Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) patients with IPF; (2) = 75 years old, Male/Female.

Exclusion criteria

Exclusion criteria: (1) can't tolerate Nitanib and Azithromycin; (2) with obvious pulmonary infections requiring anti infection treatment; (3) taking prednisone exceeding 10mg/d within 1 month before selection; (4) received immunosuppressive therapy within 1 month before selection; (5) with malignant tumors within 5 years before selection; (6) long term use (>1 week) of drugs such as amiodarone that may cause pulmonary fibrosis before selection; (7) received interferon, N-acetylcysteine, pirfenidone, or other anti fibrotic drugs within 1 month before selection; (8) participated in other drug trials within 3 months before selection; (9) other serious systemic diseases and organ dysfunction; (10) pregnant women, lactating women, or those who have recently planned to have children and are unable to take effective contraceptive measures; (11) with obvious liver and kidney dysfunction (ALT>1.5 times the upper limit of normal value; Cr higher than the upper limit of normal value); (12) researchers believe that there are any individuals who are not suitable for selection.

Design outcomes

Primary

MeasureTime frame
forced vital capacity;

Secondary

MeasureTime frame
vital capacity;diffusion capacity for carbon monoxide of lung;forced expiratory volume in the first second;6-minute walk test;chest high resolution CT;St George' s respiratory questionnaire;Borg dyspnea score;c-reactive protein;erythrocyte sedimentation rate;immunoglobulin;echocardiography;arterial blood gas analysis ;laminin;type IV collagen;type III procollagen N-terminal peptide;hyaluronic acid;

Countries

China

Contacts

Public ContactYiliang Su

Tongren Hospital, Shanghai Jiao Tong University School of Medicine

suyiliang1983@hotmail.com+86 137 6108 9437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026